Session Details

Cancer immunotherapies continue to evolve and seek to overcome challenges to expand their curative potential. One approach is to mobilize natural antitumor immunity, such as through vaccination, oncolytic virotherapy, or adoptive transfer of ex vivo expanded tumor-infiltrating lymphocytes. Another approach is to expand the reach of T cells directed against tumor-associated antigens shared by multiple patients and tumor types. The speakers in this session will highlight how innovations in these different areas will, overall, expand our immune armamentarium against cancer.